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Abstract: Type 2 diabetes (DM2) constitutes 90%–95% of the diabetes cases and is increasing 
at an alarming rate in the world. The Centers for Disease Control and Prevention (CDC) esti-
mates that more than 29 million people in the United States have diabetes, which often causes 
mortality from macrovascular complications and morbidity from microvascular complications. 
Despite these troubling facts, there is currently no widely accepted staging system for DM2 
like there is for cancer. TNM oncologic staging has taken a complex condition like cancer and 
conveyed likelihood of survival in simple alpha-numeric terms that both patients and providers 
can understand. Oncology is now entering the era of precision medicine where cancer treatment 
is increasingly being tailored to each patient’s cancer. In contrast, DM2 lacks a staging system 
and remains a largely invisible disease even though it kills more Americans and costs more to 
treat than cancer. Is a comparable staging system for DM2 possible? We propose the Diabetes 
Staging System for DM2 that utilizes macrovascular events, microvascular complications, 
estimated glomerular filtration rate (GFR), and hemoglobin A1C to stage DM2.
Keywords: type 2 diabetes, macrovascular complications, microvascular complications, hemo-
globin A1C, glomerular filtration rate, GFR, TNM cancer staging
Background
Type 2 diabetes (DM2) constitutes 90%–95% of the diabetes cases and is increasing at 
an alarming rate in the world with 425 million people affected in 2017 and 629 million 
projected in 2045. The Centers for Disease Control and Prevention (CDC) estimates 
that 29 million people in the US have DM2, which costs the US economy $322  billion.1 
More concerning is that DM2 cases are expected to rise sharply over the next 40 years 
due to an aging population, larger numbers of minority groups at higher risk to develop 
DM2, and longer life expectancy.2 Effective strategies are urgently needed to ease this 
burden on patients, the health care system, and the nation.
Disease staging systems are one approach that can help. The main objective of any 
good staging system is to indicate prognosis, facilitate information exchange, assist 
providers in planning and evaluating treatment, and aid research efforts.3 The field 
of oncology has successfully used cancer staging systems, such as TNM, Ann Arbor, 
FIGO, and Dukes, to accomplish these objectives and is now entering the era of preci-
sion medicine. A tangible example is a Phase II clinical drug trial of melanoma that 
supported “the rationale for the analysis of blood and tumor samples in future studies 
to expedite the development of more effective treatments”.4 In contrast, DM2 lacks 
a coherent staging system and physicians are not currently able to tailor treatment to 
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each patient. Thus, DM2 continues to remain a largely invis-
ible disease even though it kills more Americans and costs 
more to treat than cancer.
Only a few attempts have been made to stage diabetes 
and these approaches are not easy to use and have not 
been widely accepted.5–7 Gibson et al used macrovascular 
and microvascular complications to categorize DM2 into 
four stages with more severe macrovascular complications 
resulting in higher DM2 stage3,4 but the distinction between 
macrovascular complications seemed arbitrary at times.5 For 
example, coronary artery bypass graft resulted in DM2 stage 
3 designation while a myocardial infarction (MI) resulted 
in DM2 stage 4 designation even though both events are 
equally serious manifestations of cardiovascular (CV) dis-
ease.5 Furthermore, some microvascular complications such 
as painful diabetic neuropathy, proliferative retinopathy and 
a history of osteomyelitis and/or bacterial skin infections of 
the foot led to DM2 stage 4 similar to a patient with an MI 
but the rationale for this was not clear.5 Nonetheless, they 
did demonstrate higher mortality and costs with higher 
DM2 stage but the overall sample size was small (n = 379), 
and the aboriginal ethnicity of the study population limits 
generalizability.5 Garcia de Alba et al tested the feasibility of 
another DM2 staging called the USEISS DM2 scale using a 
retrospective cohort of 2,702 Mexican test subjects matched 
to 400 cross-sectional controls.6 USEISS DM2 stage ranged 
from 1 to 5 and incorporated primary, secondary, and tertiary 
prevention strategies to treat lower DM2 stages,1–4 while 
diabetic complications were only considered at DM2 stage 
5.6 They also used 32 distinct risk factors to stage and clas-
sify “risk control” in persons with and without diabetes and 
emphasized behavioral counseling across each DM2 stage 
which raises significant concern about how feasible this 
system would be in real-world clinic setting where 30–40 
minutes are allotted for each new type 2 diabetic patient.6 
Finally, Wu published a brief note outlining his concept 
for a DM2 staging system with five different DM2 stages.7 
Stages 1–2 did not include diabetes complications, while 
stages 3–5 did take diabetes complications into account but 
microvascular and macrovascular complications for each 
stage were not clearly defined and there was no statistical 
validation provided.7 Finally, White’s classification system 
is one of the earliest attempts to categorize diabetes but it 
was limited to pregnant woman with diabetes.8 In summary, 
prior DM2 staging attempts are admirable but limited in 
their clinical impact because they are not easy to use and 
lack robust statistical validation and generalizability due to 
ethnic differences.
The Diabetes Staging System (DSS)
We propose the DSS for DM2 that utilizes macrovascular 
events, microvascular complications, estimated glomerular 
filtration rate (GFR), and hemoglobin A1C to stage DM2. Our 
goal in proposing this staging system is to start a dialogue 
between various diabetes stakeholders that leads to further 
improvement and refinement of DSS. We also have an active 
Institutional Review Board (Brody School of Medicine at 
East Carolina University, Greenville, NC, USA) research 
protocol and are in the process of analyzing the data to see 
if it can provide preliminary validation for DSS.
Staging system overview
We modeled DSS (Figure 1) on TNM cancer staging because 
it is well validated and widely accepted. Figure 1 helps the 
reader visualize how stage and substage are determined. 
Cancer staging uses the size and extent of tumor invasion 
to determine disease stage and risk for death. Using this 
as a paradigm for diabetes staging, we sought to identify 
a parallel aspect of DM2 that progresses over time and 
increases mortality and settled on vascular disease. In DSS, 
macrovascular events are the primary driver of stage with 
higher stage conferring higher mortality. Microvascular 
complications reflect morbidity within each stage with more 
microvascular complications indicating worsening morbidity. 
In DSS, GFR and A1C are the primary drivers of substage 
that guides therapy and minimizes harm. Figure 2 shows 
how DSS would be used in clinical practice. The rationale 
for DSS is to incorporate well-validated and widely accepted 
approaches into a broader system that can stage DM2.
Macrovascular events determine the stage within 
DSS
Specifically, the number of macrovascular events or the pres-
ence of advanced chronic kidney disease (CKD) defined as 
Kidney Disease: Improving Global Outcomes (KDIGO) stage 
4 (GFR 15–29) or stage 5 (GFR < 15) are the main drivers 
of a higher diabetes stage.9 DM2 stage progresses (Figure 2) 
with number of macrovascular events as follows: Stage 1 (no 
macrovascular events) → Stage 2 (one macrovascular event) 
→ Stage 3 (two macrovascular events) → Stage 4 (three mac-
rovascular events). Macrovascular events include MI, coronary 
revascularization (coronary artery bypass graft), coronary 
stenting, abdominal aortic aneurysm repair, stroke, transient 
ischemic attack, peripheral vascular disease requiring revas-
cularization, and amputation of limb including below-knee 
amputation and above-knee amputation. Stage 5 is the highest 
stage and is reserved for patients with DM2 who have KDIGO 
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1. Normal or high (GFR ≥90)
2. Mildly decreased (GFR 60–89)






































4. Severely decreased (GFR 15–29)
5. Kidney failure (GFR <15)
Figure 1 Diabetes Staging System flow diagram for determining stage and substage.
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Figure 2 Diabetes Staging System overview.
Abbreviation: GFR, glomerular filtration rate.





stage 4 or 5 disease regardless of macrovascular events since 
advanced CKD itself confers a very high risk of death from 
a macrovascular event. The evidence to justify this approach 
comes from several large studies including two prospective 
studies, one pooled analysis, and a National Diabetes  Swedish 
Registry study evaluating cause of death in diabetes.10–13 These 
studies found renal disease and then CV disease to have the 
highest risk for death in diabetics, respectively.10–13
Microvascular complications determine the severity 
within each stage of diabetes
After DM2 stage is assigned, a numeric value between 1 and 
5, an alphabetic uppercase letter between A and D is assigned 
based on the number of microvascular complications (A 
= no microvascular complication, B = one microvascular 
complication, C = two microvascular complications, and 
D = three microvascular complications). Retinopathy is 
confirmed by a dilated eye exam, retinal photocoagulation 
(RP), vascular endothelial-growth factor inhibitor (VEGF-i) 
injection, vitreous hemorrhage, macular edema, and legal 
blindness. Nephropathy is confirmed by persistently elevated 
urine microalbumin/creatinine ratio and decreased GFR. 
Neuropathy is confirmed by a detailed foot exam that detects 
the presence of decreased sensation to light touch, pin prick, 
proprioception, vibration; a history of foot ulcer, amputation of 
toes/foot/leg, neuropathic ulcer, or Charcot foot. The evidence 
to justify the use of microvascular involvement as a marker of 
morbidity comes from several studies that show microvascular 
complications decrease health-related quality of life.14–17
Glomerular filtration and hemoglobin A1C 
determine the substage
The nomenclature for diabetes stage (numeric 1–5 and 
alphabetic uppercase A–D) is followed by nomenclature for 
 substage (numeric 1–5 and alphabetic lowercase a–d). The first 
part of the substage comprises renal function (number) and 
the second part (lowercase letter) glycemic control (Figure 2). 
Renal function is assigned a substage numeric value between 
1 and 5 (1- GFR ≥90, 2- GFR 60–89, 3- GFR 30–59, 4- GFR 
15–29, 5-GFR < 15), which corresponds to the KDIGO system 
for classifying kidney function.9 As mentioned previously and 
seen in Figure 2, the only exception is when GFR is 15–29 
or GFR < 15; in this case, the severe CKD also determines 
the stage number (5) and letter (A). The intent of the renal 
function (GFR) component is to guide therapy in the setting 
of advanced CKD (GFR < 30) by limiting patient exposure to 
oral and injectable agents contraindicated in advanced renal 
disease (ie, Metformin, Sulfonylurea, SGLT-2, TZD, and GLP-
1) and to minimize risk for hypoglycemia (ie, decrease insu-
lin), heart failure (ie, decrease dose of dipeptidyl-transferase 4 
inhibitor), and lactic acidosis (ie, decrease or stop Metformin). 
Renal dosing Recommendations
When the GFR drops to <30, the provider needs to re-
evaluate the patient diabetes regimen and some changes may 
be indicated depending on the medication. For example, 
no dose adjustment is needed for thiazolidinediones, bile 
acid sequestrants, Dopamine 2-agnoists and Amylin.34 Dose 
adjustment is needed for Repaglinide/Nateglinide, Glipizide/
Amaryl, DPP4-inhibitors and insulin.34 However, discontinu-
ation is needed for Metformin, Alpha-glucosidase inhibitors, 
Glyburide, Glucagon-like-peptide I and SGLT-2 inhibitors.34
Glycemic control measured by A1C comprises the second 
part of the substage and is assigned a lowercase letter (a: <7%, 
b: 7%–8.5%, c: 8.6%–10%, d: >10%). In the event that A1C is 
confounded by conditions that affect red blood cell turnover (ie, 
hemolytic anemia, recent blood transfusion, drugs that stimu-
late erythropoiesis, end-stage kidney disease, and pregnancy), a 
calculator (http://professional.diabetes.org/eAG) that converts 
A1C to estimated average glucose (eAG) as follows will be 
used: <7% → <154 mg/dL, 7%–8.5% → 154–200 gm/dL, 
8.6%–10% → 200–240 mg/dL, >10% →>240 mg/dL. Since 
most blood glucose monitors provide 7-day, 14-day, and 30-day 
blood glucose average, we will use the 30-day blood glucose 
average as a surrogate for A1C to determine the second part 
of the substage. Glycemic control has been shown to predict 
likelihood to develop microvascular complications in DM2,18 
and its intent is to help overcome clinical inertia to treatment 
intensification when glycemic goals are not being met.
Significance
DM2 is a pervasive and costly condition to treat like cancer. 
While there are stark differences in the two conditions, both 
involve gradual progression of a disease and the availability 
of various treatment modalities. Given the amount of infor-
mation a provider has to deal with when managing a patient 
with diabetes, we wanted to create a simplified system of clas-
sification that can do for diabetes what staging has done for 
cancer. We especially liked the straightforward alphanumeric 
TNM cancer classification given its ability to stage cancer, 
predict mortality, and guide treatment. In so doing, a complex 
condition is simplified in a way that allows patients and pro-
viders to understand what is at stake and what can be done.
We acknowledge that unlike cancer, diabetes does not 
have a similar linear progression so it is difficult to stage in 
a similar way. The other important point to remember with 
DSS stage is that it does not move backward to a lower stage, 
it can only progress to a higher stage. A higher DSS stage 
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is considered if additional macrovascular or microvascular 
complications have developed over the past year. On the other 
hand, the substage is more variable since it is determined by 
GFR and A1C which may change based on several factors. 
Nonetheless, DSS still provides a simplified communica-
tion mechanism between providers with easy-to-follow 
 categorization that can be useful in many scenarios, some 
of which have been highlighted.
improved ability to predict survival
DSS would allow patients and providers to have a more 
meaningful discussion about likelihood of survival that has 
not previously been available. The absence of this infor-
mation has in our view undermined efforts to encourage 
lifestyle changes that promote better diet and exercise. In 
contrast, TNM cancer staging’s ability to quantify mortality 
has helped providers and patients focus on interventions 
that help them live longer. The focus on helping DM2 
patients live longer is particularly relevant now because 
recently completed clinical trials such as LEADER and 
EMPA-REG have for the first time shown that Liraglutide 
and Empagliflozin prolong life in DM2 patients with 
established CV disease.19,20 Since DSS incorporates mac-
rovascular events, it could help guide providers to prefer-
entially prescribe Liraglutide and/or Empagliflozin in DM2 
patients with known CV disease (Figure 3) with established 
CV disease, which would be DSS stages 2–4.19,20 Further-
more, DSS would be flexible enough to allow other agents 
demonstrating a mortality benefit in DM2 patients to be 
added in the future so that this system would adapt to new 
emerging therapies.
improved ability to guide therapy toward best 
practices for DM2
Primary care providers, clinical pharmacists, and endocrinolo-
gists represent the first and often only line of defense for many 
patients with DM2. During a 30–40-minute visit, they must 
somehow convey the seriousness of the disease while navigat-
ing the myriad 30+ treatment options to find the safest and 
most effective regimen that will help improve DM2 outcomes. 
Too many choices sometimes make it difficult to decide which 
agent to use. Although a formulary system helps reduce 
treatment options, providers are still left with many choices. 
The DSS could help in this regard by highlighting evidence-
based interventions that have been shown to help improve 
macrovascular and microvascular complications while also 
avoiding certain agents that may cause harm.  Figures 3 and 
4 provide a practical example of an evidence-based “cheat 
sheet”, which could be made available to providers to reflect 
the current “state of the art” for DM2 care.
PCSK9 inhibitors
DM2 patients with DSS stages 2–4 disease who are continu-
ing to have CV events despite high-intensity statins could 
also be candidates for further low-density lipoproteins 
(LDL) lowering using the newer PCSK9 inhibitors which 
have demonstrated robust LDL lowering below 70 mg/dL 
and decreased CV mortality in high-risk patients.21,22 DSS 
Figure 3 Diabetes Staging System stage based interventions.
Abbreviations: ACe, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, aspirin; Cv, cardiovascular; DSS, Diabetes Staging System; 
EMPA, empagliflozin; FF, fenofibrate; GP, gabapentin; PCSK9, proprotein convertase subtilisin/kexin type 9; PG, pregabalin; RP, retinal photocoagulation; SNRI, serotonin 
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could help health care systems and its providers make more 
rational treatment decisions by only selecting patients who 
have failed proven therapies (ie, aspirin, statin, Empagliflozin, 
and Liraglutide) that are more affordable.
Treating diabetic retinopathy, 
nephropathy, and neuropathy
Several studies have shown benefit of RP, VEGF-I, and 
Fenofibrate23–25 in treating diabetic retinopathy. With regard 
to diabetic nephropathy, large clinical trials have shown that 
angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers are effective in preventing onset and pro-
gression of nephropathy.26,27 Gabapentin, pregabalin, tricyclic 
antidepressants, and serotonin–Norepinephrine Reuptake 
Inhibitors have been shown to be effective in improving 
neuropathic pain.28–31 Figures 3 and 4 provide a summary of 
the key items discussed above that would be incorporated 
into DSS and could be developed into a best practice “cheat 
sheet” that providers could use so that beneficial interventions 
are not overlooked and patient harm is avoided.
improved ability to predict cost
DSS may also allow health care systems to better predict 
DM2-related costs since it takes the number and severity of 
DM2-related macrovascular/microvascular complications 
into account. For example, DSS could help refine Health 
Data Information Set (HEDIS), which is currently used by 
most private health care plans to measure “quality of care” 
for chronic conditions such as DM2. All type 2 diabetics 
are currently treated the same by HEDIS but DSS could be 
used to more accurately reflect severity of macrovascular/
microvascular complications in DM2 patients, which would 
help create better “buy in” from providers and health care 
systems because they would know that disease acuity is being 
considered rather than a “one size fits all” approach that shifts 
all the risk of severe DM2 care on them.
Public awareness
DSS can also be used to increase patient and public awareness 
about the seriousness of DM2 like TNM has done for cancer. 
Unfortunately, diabetes suffers from a public perception that 
it is a chronic disease much like hypertension that does not 
really kill its victim or progress to any real extent. The public 
has a very visceral “fight or flight” response when the word 
cancer is spoken. Central to this narrative is the ability of 
cancer staging to quantify in simple terms the likelihood of 
death. Since the public is already aware of cancer staging, 
using a similar approach for DM2 could help change the 
public’s perception of DM2. Telling someone to change their 
diet and exercise because they have DM2 is one thing, but 
quantifying their risk of death may more strongly motivate 
the patient to change their diet and exercise behavior.
Clinical trials
Pharmaceutical companies are always seeking more efficient 
ways to conduct clinical trials. One core element in conduct-
ing a clinical trial is recruiting the right patient population. 
DSS could make it easier for pharma companies to recruit 
patients for large multi-center studies by creating a single 
line statement that reflects CV disease, microvascular com-
plications, GFR, and current glycemic control. This would 
improve communication between key stakeholder such as 
pharma companies, the FDA, physicians, and patients. Since 
the FDA is currently requiring all novel agents for DM2 to 
Figure 4 Diabetes Staging System substage based interventions.
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demonstrate CV safety, a hypothetical pharma trial could use 
the DSS to target recruitment of diabetic patients with a stage 
2–4 disease and to exclude stage 1 and 5 patients due to low 
likelihood of CV events or very high CV risk, respectively. 
Stage 5A patients may also be excluded or require additional 
monitoring due to their higher vascular risk and inability to 
clear drugs that are cleared by the kidney. Finally, the DSS 
could also help pharmaceutical companies to more easily 
define the patient population best suited for treatment of 
effective but very expensive agents such as PCSK9 inhibitors.
Conclusion
Gerber et al noted that in learning machines and humans, 
the relationship between information load and information 
handling takes the shape of an inverted U.32 As information 
load increases, so does the ability to handle information but 
only up to a certain point after which the ability to handle 
information declines and errors increase. We believe this is 
one of the factors at play in the clinical management of DM2 
that leads to inertia. In fact, clinical inertia is overwhelmingly 
the major reason that patients remain poorly controlled for 
years.33 We feel that inertia is occurring in part because of 
information overload especially in primary care practices. 
Providers often have to deal with multiple chronic diseases 
during a single visit. For example, there are 34 agents for 
DM2 and the 2018 ADA standards of care is 153 pages 
long. How can a primary care provider keep up with such 
information? DSS can help by distilling the best available 
scientific evidence into a logical framework that is easy to 
follow. Specifically, DSS can help clinical inertia in the fol-
lowing three important ways: 1) Improving understanding 
by streamlining communication between providers and with 
patients for better coordination and management of diabe-
tes; 2) Increasing survival by emphasizing the importance 
of CV disease and steering providers toward agents proven 
to lower CV mortality (ie, Empagliflozin, Liraglutide); and 
3) Avoiding harm by including an expansive list of diabetic 
medications (Figure 4) and recommended actions when GFR 
falls to <30, which will help the provider make an informed 
decision that balances risk vs benefit.
To our knowledge, TNM cancer staging has not been 
previously used as a template for a DM2 staging system. We 
acknowledge that DSS needs to be validated and are actively 
working to accomplish this important next step. We also are 
aware that DM2 patients with a lower DSS stage may not get 
as much clinical attention as those with established CV events. 
However, we would like to emphasize that we strongly believe 
that DSS should be evidence based so if new data emerge 
demonstrating a particular diabetic medicine to be effective 
for primary prevention of CV disease then we would be the 
first to incorporate it into DSS. We also accept that diet and 
lifestyle play a very important role in management of DM2 
and that changing human behavior is one of the most difficult 
things to accomplish in medicine. However, we feel that the 
DSS can help change patient perception of their diabetes from 
a “nebulous” condition to one where they can “see” severity 
and progression through a simple, step-wise staging system 
which could motivate them to become more engaged in 
improving their diabetes through lifestyle, diet, and exercise.
This special article shares our vision for DSS and seeks 
constructive criticism, feedback, and suggestions from col-
leagues in the field on how to improve on it. In so doing, we 
hope that a staging system can be refined over time that is 
widely adopted by all stakeholders impacted by the disease 
and that it can make a meaningful impact in improving care 
and outcomes for DM2, and thereby improving the lives of 
our patients who have diabetes.
Case study
A 53-year-old white male with a past medical history of 
hypertension, hyperlipidemia, obesity, coronary artery dis-
ease requiring cardiac stenting, and DM2 presents to our 
clinic. The patient has had DM2 for the past 10 years. He 
has had one macrovascular complication namely cardiac 
ischemia requiring stenting. He is also noted to have diabetic 
nephropathy and retinopathy based on an elevated urine 
microalbumin/creatinine ratio and recent dilated eye exam, 
respectively. Physical examination is positive for decreased 
sensation to a 5.07 Semmes-Weinstein monofilament and 
decreased vibratory and position sense in both feet. Sensa-
tion to pinprick is normal. Lab results show the following: 
hemoglobin A1C 9%, GFR 55, urine microalbumin/cre-
atinine ratio 120 mg/gCr, and finger stick blood sugar 200 
mg/dL. Fasting lipid panel: total cholesterol 180 mg/dL, 
high-density lipoproteins 45 mg/dL, LDL 99 mg/dL, and 
triglycerides 150 mg/dL. Current medication: Metformin 
1,000 mg twice per day, Amaryl 4 mg twice per day, Aspirin 
81 mg qd, and Lipitor 40 mg qd.
what is this patient’s stage using DSS?
Stage depends on the number of macrovascular events and 
microvascular complications (Figure 2). This patient has one 
macrovascular event (ie, CAD requiring stenting) and three 
microvascular complications such as diabetic nephropathy 
(ie, patient has urine screen positive for moderate microalbu-
minuria), diabetic retinopathy (ie, patient’s dilated eye exam 





that showed retinopathy), and diabetic neuropathy (physical 
exam showed decreased sensation to light touch). Therefore, 
looking at Figure 2 makes patient’s stage 2D.
Substage is listed next to stage and is determined by GFR 
and hemoglobin A1C. This patient’s GFR is 55 and A1C is 
9%. Therefore, looking at Figure 2 this patient’s substage is 
3c (Figure 2).
Therefore, this patient’s overall stage is 2D3c.
is there anything more that could be done to 
lower his Cv risk? How could the DSS help in this 
situation?
Recent randomized clinical trials such as LEADER and 
EMPA-REG have shown lower mortality vis-à-vis placebo 
in type 2 diabetic patients with established CV disease 
who were randomized to Empagliflozin and Liraglutide, 
respectively.19,20 Since the DSS accounts for macrovascular 
events, it could guide clinicians to more systematically 
consider Liraglutide and/or Empagliflozin in DM2 patients 
with established CV disease, which according to our staging 
system would be stages 2–4.19,20 Since our patient has stage 
2 disease and has already had one macrovascular event, he 
does merit consideration for Liraglutide or Empagliflozin 
even though he is on an ASPIRIN and STATIN. Stage 5 
patients would be contraindicated due to advanced CKD. 
The primacy of vascular disease in determining DM2 stage 
makes it possible for other diabetes agents that demonstrate 
CV mortality reduction to be added to Liraglutide and 
Empagliflozin.
The patient is concerned about his future risk for a cardiac 
event since he has already had a CV event. He cites fears 
that his brother died of an MI in his fifties, and he does not 
want to be next as he has two young children and a wife. He 
wonders whether more could be done to lower his CV risk 
beyond taking Aspirin and Lipitor. He is aware of recent 
clinical trials of Liraglutide, Empagliflozin and PCSK9 
inhibitors that have decreased CV mortality and wonders if 
he is a candidate for any of these agents.
He wonders if he is a candidate for this agent 
instead. How could the DSS help in this situation?
DM2 patients with DSS stage 2–4 disease who are continu-
ing to have CV events despite high-intensity statins could be 
candidates for further LDL lowering using the newer PCSK9 
inhibitors which have demonstrated robust LDL lowering 
below 70 mg/dL and were very recently demonstrated to 
decrease CV mortality in high-risk patients.21,22 However, 
there are a couple of reasons why our patient should not 
be considered at this time for this therapy. First, his Lipitor 
dose could be increased further from 40 mg to 80 mg qd 
as tolerated. Second, either Empagliflozin or Liraglutide 
is being added to further decrease CV risk and sufficient 
time needs to be given to these agents before consideration 
of an even more expensive agent. In this case, DSS could 
help physicians and health insurers make a more rational 
decision by trying two other proven less costlier options 
before considering a much more expensive option such as 
a PCSK9 inhibitor.
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